Panitumumab Pivotal Study Shows Increase In Progression-Free Survival
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen/Abgenix say twelve-month survival data will be released by second quarter. Rolling BLA submission will begin by year-end, wrapping up in early 2006.
You may also be interested in...
Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer
Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.
Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer
Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.
Amgen To Acquire Panitumumab Development Partner Abgenix
The companies plan to submit a BLA for colorectal cancer agent panitumumab later this week.